EUVIMEDEUVIMED entdecken
Crossref

Clinical change 2 years from start of elexacaftor‐tezacaftor‐ivacaftor in severe cystic fibrosis

Karen S McCoy iD, Jill Blind iD, Terri Johnson, Patti Olson, Laura Raterman, Shasha Bai, Mariah Eisner, Shahid I Sheikh iD, Stephan Druhan, Cody Young, Kimberly Pasley

Pediatric Pulmonology · 2023-04 · 58 (4) · 1178-1184

DOI: 10.1002/ppul.26318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 27.01.2023. Verfasst von Karen S McCoy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary and Sleep Medicine Division, Nationwide Children's Hospital, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

Limited published research is available on the impact of elexacaftor/tezacaftor/ivacaftor (ETI) beyond the initial few months postdrug initiation, especially for those who initiated therapy via individual investigational new drug application. The experiences of patients with cystic fibrosis (CF) experiencing severe lung disease were reviewed for significant improvements in clinical symptoms and quality of life.

Objectives

To examine clinical outcomes 2 years post‐ETI in patients with CF and advanced lung disease.

Methods

This single center institutional review board‐approved, retrospective chart review assessed clinical markers (percent predicted forced expiratory volume in 1 s, weight, sweat chloride), quality of life and computed tomography scans in patients with advanced lung disease who met criteria for compassionate use/expanded access program due to high risk of death or transplant need within 2 years.

Results

Eighteen identified patients (ages 15−49 years) initiated drug between July and September 2019. Clinical markers indicated that therapy was well tolerated, not discontinued by any participant, and lab values did not indicate medical concern or discontinuation. Monitoring results indicated the safety of modulator therapy as there were no adverse clinical occurrences and all patients presented universal stabilization. There were no deaths and no transplants by the end of the study.

Conclusions

This study focused on patients with CF eligible for modulator therapy and were initiated due to advanced lung disease. Initiation of modulator therapy was deemed safe and resulted in objective positive changes in nutrition, cough, FEV 1 , subjective reports of clinical status, level of activity, and a reduction in burden of treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansAdolescentYoung AdultAdultMiddle AgedCystic Fibrosis Transmembrane Conductance RegulatorQuality of LifeRetrospective StudiesAminophenolsBenzodioxolesMutationChloride Channel AgonistsPyrazolesPyridinesPyrrolidinesQuinolonesIndoles

Stichwörter der Autor:innen

advanced lung diseasecompassionate usecystic fibrosis

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesChloride Channel AgonistselexacaftorPyrazolesPyridinesPyrrolidinesivacaftorQuinolones

Autor:innen und Institutionen

  • Pulmonary and Sleep Medicine Division, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Investigational Pharmacy, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Department of Pediatrics at Emory University School of Medicine, Pediatric Biostatistics Core, Atlanta, Georgia, USA.
  • Biostatistics Resource, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Department of Radiology, New York University Grossman School of Medicine, New York, New York, USA.
  • Radiology Department, Nationwide Children's Hospital, Columbus, Ohio, USA.

ORCID-Profile: Karen S McCoy, Jill Blind, Shahid I Sheikh

Zitieren

APA

McCoy, K. S., Blind, J., Johnson, T., Olson, P., Raterman, L., Bai, S., Eisner, M., Sheikh, S. I., Druhan, S., Young, C., & Pasley, K. (2023). Clinical change 2 years from start of elexacaftor‐tezacaftor‐ivacaftor in severe cystic fibrosis. Pediatric Pulmonology, 58(4), 1178-1184. https://doi.org/10.1002/ppul.26318

Vancouver

McCoy KS, Blind J, Johnson T, Olson P, Raterman L, Bai S, et al. Clinical change 2 years from start of elexacaftor‐tezacaftor‐ivacaftor in severe cystic fibrosis. Pediatric Pulmonology. 2023;58(4):1178-1184. doi:10.1002/ppul.26318

BibTeX
@article{McCoy2023,
  author = {McCoy, Karen S and Blind, Jill and Johnson, Terri and Olson, Patti and Raterman, Laura and Bai, Shasha and Eisner, Mariah and Sheikh, Shahid I and Druhan, Stephan and Young, Cody and Pasley, Kimberly},
  title = {Clinical change 2 years from start of elexacaftor‐tezacaftor‐ivacaftor in severe cystic fibrosis},
  journal = {Pediatric Pulmonology},
  year = {2023},
  volume = {58},
  number = {4},
  pages = {1178--1184},
  doi = {10.1002/ppul.26318}
}
Kostenlos starten →